“It’s a great pleasure to receive this grant to carry out such a clinically significant project for a large and vulnerable group of patients. It has been a long journey, and this is very much a team effort together with our co-applicants in the US, the entire BioFINDER group and, not least, my research colleagues Niklas Mattsson-Carlgren and Erik Stomrud,” says Sebastian Palmqvist, associate professor of neuroscience and senior lecturer in neurology.
The project is led by Sebastian Palmqvist, the principal investigator at Lund University. It will be carried out in collaboration with three American universities – Washington University in St. Louis, the University of Pennsylvania and the University of Alabama – over a five-year period from 2026 to 2031. The project will involve cohorts in Sweden and the US. The grant is the largest grant from a US funder that Lund University has secured in competition to date.
“The fact that an NIH grant of this calibre is being led from Lund University is strong international recognition of Sebastian Palmqvist and his colleagues in our Alzheimer’s research. It is particularly encouraging since it demonstrates how cross-border collaboration also translates into tangible benefits for patients. The development of a new blood-based clinical test could make a real difference to both patients and the healthcare system,” says Erik Renström, Vice-Chancellor of Lund University.
Read full article: SEK 190 million for research and development of a new diagnostic test for Alzheimer’s disease.